In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ritter Pharmaceuticals (NASDAQ: RTTR), with a price target of $15. The company’s shares closed yesterday at $2.75, close to its 52-week low of $1.83.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -1.9% and a 38.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Ritter Pharmaceuticals is a Moderate Buy with an average price target of $15.
See today’s analyst top recommended stocks >>
Based on Ritter Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.01 million. In comparison, last year the company had a GAAP net loss of $1.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
